Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2019 Earnings Conference Call Transcript

Nov 07, 2019 • 08:00 am ET

Previous

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2019 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics Third Quarter 2019 Financial Results Conference Call. [Operator Instructions] Later, there will be a question and answer session, instructions will follow at that time. [Operator Instructions]

I would now like to turn the conference over to your host Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.

Executive
Mark Jacobson

Thank you, operator. Good morning and thank you all for joining us on today's conference call. Our earnings press release providing a corporate update and details of the company's financial results for the third quarter of 2019 crossed the wire a short time ago and is available on our website at www. Axsome.com. During today's call we will be making certain forward-looking statements. These statements may include statements regarding among other things the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and funding of future clinical trials, regulatory plans, future research and development and possible intended use of cash and investment. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause results to differ materially from those contained in the forward-looking statements.

These and other risks are described in our periodic filings made with the Securities and Exchange Commission including our quarterly and annual reports. You are cautioned not to place undue weight on these forward-looking statements and the company disclaims any obligation to update such statements. Joining me on the call today are Dr. Herriot Tabuteau, Chief Executive Officer who will begin the call by highlighting our recent achievements and upcoming clinical milestones; Dr. Cedric O'Gorman, Senior Vice President of Clinical Development and Medical Affairs; Dave Marek, our Chief Commercial Officer; Nick Pizzie, Chief Financial Officer who will provide a financial update. I would now like to hand the call over to Herriot.

Executive
Herriot Tabuteau

Thank you, Mark. Good morning, everyone and thank you all for joining us on the call today. So far, 2019 has been very productive for Axsome. We've significantly advanced our three clinical stage CNS product candidates, which are being evaluated in six efficacy trials, including five Phase three trials and one Phase two trial across five different indications. It is a highly active time for Axsome and a potentially important time for patients and clinicians as these studies are fast approaching completion with top line results expected by year-end for several of these clinical trials. If successfully developed, our first-in-class or best in class investigational medicines have the potential to transform the lives of many of the millions of patients who are currently failed by existing treatments for their CNS disorders. Before I provide an update on our programs and upcoming clinical milestones, I would like to introduce you to our Chief Commercial Officer, Dave Marek, who joined the Axsome team in August. Dave joins us from Amgen, where he was Vice President and General